Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+12.29%
+4.37%
+6.14%
+2.42%
+18.53%
VKTX
Viking Therapeutics
$33.93
Chart
$26.12 (+29.90%)
$23.94 (+41.73%)
$28.68 (+18.31%)
$61.25 (-44.60%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+12.29%
+4.37%
+6.14%
+2.42%
+18.53%
VKTX
Viking Therapeutics
Current Price
$33.93
Login to view Viking Therapeutics (VKTX) recommendation from the last 90 days from financial news and social media.
Chart
$26.12 (+29.90%)
$23.94 (+41.73%)
$28.68 (+18.31%)
$61.25 (-44.60%)
VKTX Latest Analysis
Behind the Scenes of Viking Therapeuticss Latest Options Trends. Investors with a lot of money to spend have taken a bearish stance on ).And retail traders should know.We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with VKTX it often means somebody knows something is about to happen.Today Benzinga'.s option
Fri Jul 25, 2025
Viking Therapeutics Q2: Confidently Continuing The Recovery.
Fri Jul 25, 2025
Viking Therapeutics Posts Wider Q2 Loss. Key Points- Loss per share was $(0.58) falling short of analyst expectations by $(0.13) or 29.1% (GAAP Q2 2025).
Wed Jul 23, 2025
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update. Conference call scheduled for Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed. Top-Line Results Expected 2H25Continued Progress with Amylin Program. IND Planned 4Q25Strong Quarter-End Cash Position of ) a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders
Wed Jul 23, 2025
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates. ) shares are falling in Wednesday’.s after-hours session after the company reported financial results .estimates for a loss of 46 cents per share according to Benzinga Pro.The clinical-stage biopharmaceutical company said research and development expenses totaled$60.2 millionin the second quarter up from $23.8 million in the prior year’.s quarter. Viking Therapeutics ended the period with $808 ...
Wed Jul 23, 2025
Viking Therapeutics EPS miss sends shares down 7%.
Wed Jul 23, 2025
Viking Therapeutics GAAP EPS of -$0.58 misses by $0.12.
Wed Jul 23, 2025
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX) Sets a $102 PT.
Wed Jul 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
VKTX Stock trends
VKTX Stock performance
VKTX Stock analysis
VKTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings